Early and Late Onset Neonatal Sepsis (EONS and LONS)and Intra-Amniotic Infection (Triple I)

Table of Criteria for Early and Late Onset Neonatal Sepsis (EONS and LONS) and Intra-Amniotic Infection (Triple I)

Summary

This table provides a clear and concise overview of the criteria for diagnosing Early-Onset Neonatal Sepsis (EONS), Late-Onset Neonatal Sepsis (LONS), and Intra-Amniotic Infection (Triple I). It includes essential information on the time of onset, common etiologies, risk factors, clinical presentations, and diagnostic measures for each condition. This structured approach aids in the prompt identification and effective management of these serious conditions, ultimately improving maternal and neonatal outcomes.

---

Early and Late Neonatal Sepsis

Neonatal sepsis is a critical condition characterized by systemic infection in the newborn. It can be classified based on the time of onset into early-onset sepsis (EOS) and late-onset sepsis (LOS). Understanding the differences in etiology, clinical presentation, diagnosis, and management is essential for effective treatment and improving outcomes.

Early-Onset Neonatal Sepsis (EONS)

Time of Onset: Occurs within the first 72 hours of life.

Etiology:

• Typically acquired from the maternal genital tract during delivery.
• Common pathogens include Group B Streptococcus (GBS), Escherichia coli, Listeria monocytogenes, and other Gram-negative bacteria.

Risk Factors:

• Premature rupture of membranes (PROM) for more than 18 hours.
• Maternal chorioamnionitis.
• Preterm birth (less than 37 weeks gestation).
• Maternal GBS colonization.
• Intrapartum fever.

Clinical Presentation:

• Respiratory distress (e.g., tachypnea, grunting, nasal flaring, cyanosis).
• Apnea.
• Temperature instability (hypothermia or fever).
• Poor feeding.
• Lethargy or irritability.
• Hypotension.
• Jaundice.

Diagnosis:

• Blood Cultures: Essential for identifying causative organisms.
• Complete Blood Count (CBC): May show elevated white blood cells (leukocytosis) or low white blood cells (leukopenia), and thrombocytopenia.
• C-Reactive Protein (CRP): Elevated levels can indicate inflammation or infection.
• Lumbar Puncture: Performed if meningitis is suspected to analyze cerebrospinal fluid.
• Chest X-ray: If respiratory symptoms are present to identify pneumonia or other complications.

Management:

• Empirical Antibiotic Therapy:
  • Ampicillin and Gentamicin or Cefotaxime.
• Supportive Care:
  • Respiratory support (oxygen therapy, mechanical ventilation).
  • Intravenous fluids to maintain hydration and electrolyte balance.
  • Monitoring of vital signs, blood glucose, and electrolytes.
• Duration of Therapy: Typically 10-14 days, adjusted based on culture results and clinical response.

---

Late-Onset Neonatal Sepsis (LONS)

Time of Onset: Occurs after the first 72 hours of life, up to 28 days.

Etiology:

• It is often acquired postnatally from the environment, healthcare settings, or caregivers.
• Common pathogens include coagulase-negative staphylococci (CoNS), Staphylococcus aureus, Escherichia coli, Klebsiella spp., and fungal organisms (e.g., Candida).

Risk Factors:

• Prematurity and low birth weight.
• Central venous catheter use.
• Prolonged hospitalization.
• Invasive procedures (e.g., mechanical ventilation, surgery).
• Compromised immune system.

Clinical Presentation:

• Similar to EOS but may also include:
  • Seizures.
  • Bulging fontanelle (if meningitis is present).
  • Localized infections (e.g., abscesses, cellulitis).
  • Irritability or hypotonia.
  • Abdominal distension.

Diagnosis:

• Similar to EOS, with additional investigations based on clinical presentation.
• Consider imaging studies (e.g., ultrasound, MRI) if localized infection or abscess is suspected.

Management:

• Empirical Antibiotic Therapy:
  • Vancomycin plus an aminoglycoside (e.g., Gentamicin) or a third-generation cephalosporin (e.g., Cefotaxime).
  • Adjust antibiotics based on culture results and antibiotic susceptibility.
• Supportive Care:
  • Similar to EOS, including respiratory support, intravenous fluids, and monitoring.
• Duration of Therapy: Typically 14-21 days, adjusted based on culture results and clinical response.

---

Intra-amniotic infection (Triple I)

Intra-amniotic infection, also known as Triple I (Intrauterine Infection or Inflammation), refers to the presence of infection or inflammation within the amniotic cavity. It is a serious condition that can affect both the mother and the fetus, leading to significant morbidity and mortality.

Pathophysiology: Triple I often occurs due to the ascent of bacteria from the lower genital tract into the normally sterile amniotic cavity. This can happen at any point during pregnancy but is more common in cases of prolonged labor, premature rupture of membranes (PROM), or invasive procedures.

Etiology:

• Common pathogens include Group B Streptococcus, Escherichia coli, Ureaplasma urealyticum, Mycoplasma hominis, and anaerobes (e.g., Bacteroides spp.).
• Polymicrobial infections are also common.

Risk Factors:

• Prolonged rupture of membranes (PROM).
• Preterm premature rupture of membranes (PPROM).
• Prolonged labor.
• Multiple vaginal examinations during labor.
• Invasive procedures (e.g., amniocentesis).
• Nulliparity.
• Pre-existing infections (e.g., bacterial vaginosis).

Clinical Presentation:

• Maternal Signs:
  • Fever (>38°C or 100.4°F).
  • Maternal tachycardia (>100 beats per minute).
  • Uterine tenderness.
  • Foul-smelling amniotic fluid.
  • Leukocytosis (elevated white blood cell count).
• Fetal Signs:
  • Fetal tachycardia (>160 beats per minute).
  • Reduced fetal movement.
  • Abnormal fetal heart rate tracing.

Diagnostic Criteria: The diagnosis of intra-amniotic infection (Triple I) is primarily clinical but can be supported by laboratory findings. The criteria include:

• Maternal Fever: A single temperature ≥39°C (102.2°F) or a temperature between 38°C and 39°C (100.4°F to 102.2°F) on two occasions, 30 minutes apart.
• Plus one or more of the following:
  • Maternal leukocytosis (>15,000 cells/mm³).
  • Purulent cervical discharge.
  • Fetal tachycardia (>160 beats per minute).
  • Biochemical markers in amniotic fluid (e.g., elevated interleukin-6, decreased glucose, Gram stain positive for bacteria).

Management:

• Antibiotic Therapy:
  • Empirical Antibiotics: Begin with broad-spectrum antibiotics that cover the most common pathogens.
  • Example regimen: Ampicillin (2 g IV every 6 hours) plus Gentamicin (5 mg/kg IV every 24 hours).
  • For Penicillin-Allergic Patients: Clindamycin (900 mg IV every 8 hours) plus Gentamicin (5 mg/kg IV every 24 hours).
  • Add Anaerobic Coverage: If there is a strong suspicion of anaerobic infection, consider adding Metronidazole (500 mg IV every 8 hours) or using Clindamycin.
• Delivery:
  • Expedite delivery if intra-amniotic infection is diagnosed, especially if the pregnancy is near term.
  • For preterm pregnancies, balance the benefits of delivery against the risks of prematurity. Continuous monitoring and timely intervention are crucial.
• Supportive Care:
  • Maternal and fetal monitoring.
  • Hydration and antipyretics for fever management.
  • Respiratory support for the neonate if required after birth.
• Postpartum Care:
  • Continue antibiotics for at least 24-48 hours postpartum or until the mother is afebrile for 24 hours.
  • Monitor for complications such as endometritis and neonatal sepsis.

Detailed Dosage:

• Penicillin G for GBS Prophylaxis:
  • Initial Dose: 5 million units IV.
  • Maintenance Dose: 2.5 million units IV every 4 hours until delivery.
• Cefazolin for GBS Prophylaxis (Penicillin Allergy - Low-risk Anaphylaxis):
  • Initial Dose: 2 g IV.
  • Maintenance Dose: 1 g IV every 8 hours until delivery.
• Clindamycin for GBS Prophylaxis (Penicillin Allergy - High-risk Anaphylaxis):
  • Dosage: 900 mg IV every 8 hours until delivery.
• Vancomycin for GBS Prophylaxis (Penicillin Allergy - High-risk Anaphylaxis):
  • Dosage: 1 g IV every 12 hours until delivery.
• Ampicillin for PPROM Prophylaxis:
  • IV Dosage: 2 g IV every 6 hours for 48 hours.
  • Oral Dosage: Amoxicillin 250 mg orally every 8 hours for 5 days.
• Erythromycin for PPROM Prophylaxis:
  • Dosage: 250 mg orally every 6 hours for 7 days.
• Ampicillin for Triple I Management:
  • Dosage: 2 g IV every 6 hours.
• Gentamicin for Triple I Management:
  • Dosage: 5 mg/kg IV every 24 hours.
• Clindamycin for Triple I Management (Penicillin Allergy):
  • Dosage: 900 mg IV every 8 hours.
• Metronidazole for Anaerobic Coverage:
  • Dosage: 500 mg IV every 8 hours.

Respiratory Support for Neonates:

• Indications:
  • Neonates born preterm.
  • Infants are showing signs of respiratory distress.
  • Confirmed or suspected intra-amniotic infection affecting the fetus.
• Supportive Measures:
  • Nasal Cannula:
    • Indication: Mild respiratory distress.
    • Method: Administer low-flow oxygen via nasal cannula to maintain oxygen saturation levels.
  • Continuous Positive Airway Pressure (CPAP):
    • Indication: Moderate respiratory distress in preterm infants or those with surfactant deficiency.
    • Method: Administer CPAP via nasal prongs or mask to keep the airways open and improve gas exchange.
  • Positive Pressure Ventilation (PPV):
    • Indication: Severe respiratory distress, apnea, or inadequate oxygenation/ventilation despite CPAP.
    • Method: Administer PPV via endotracheal intubation and mechanical ventilation. Adjust settings based on the infant's respiratory status and blood gas levels.
  • Surfactant Therapy:
    • Indication: Neonates with confirmed or suspected surfactant deficiency (e.g., Respiratory Distress Syndrome).
    • Method: Administer surfactant intratracheally as soon as possible after birth for those who meet the criteria.

Conclusion

Neonatal sepsis and intra-amniotic infection (Triple I) are serious conditions requiring prompt recognition and intervention. Early-onset sepsis (EOS) and late-onset sepsis (LOS) differ in their time of onset, etiology, and management strategies. Triple I, characterized by infection or inflammation within the amniotic cavity, demands immediate antibiotic therapy and often necessitates expedited delivery. Comprehensive management, including appropriate antibiotic regimens, supportive care, and respiratory support for neonates, is crucial for improving maternal and neonatal outcomes. Preventive measures such as GBS screening and prophylaxis for high-risk pregnancies play a vital role in reducing the incidence of these infections. Through vigilant monitoring, timely intervention, and adherence to clinical guidelines, healthcare providers can significantly enhance the prognosis for affected mothers and their newborns.